MANCH



### Discovering Sub-diseases with Model-based Machine Learning

Iain Buchan

Director, Farr Institute @ Health eResearch Centre

Director, Centre for Health Informatics, University of Manchester

23<sup>rd</sup> September 2015

Machine Learning for Personalized Medicine Summer School, Manchester

# **Endotype Discovery**

Aim to identify **subgroups** ("endo-phenotypes" or "endotypes") of disease risk or treatment outcome explained by a **distinctive** underlying **mechanism** 

Foundation of **Stratified Medicine**, seeking better-targeted interventions



M.C. Escher Order and Chaos, 1950



# Asthma: Low GWAS Yield

 Legacy of non-replicated genetic epidemiology, typical of most common chronic disorders

🛧 Linkage in 1 study only

 $\star$  Linkage in >1 study





# **Asthma: Gene** $\cup$ **Environment**

 Important gene-environment interaction information may be averaged out in narrow or aggregated studies

CD14 Endotoxin Receptor

 $\bigstar$  C allele associated

 $\star$  T allele associated

 $\star$  No association



![](_page_3_Picture_7.jpeg)

# **Asthma: Heterogeneity**

- Usually starts early in life, and may progress, remit or relapse over time
- Single cohort study hypothesis-driven epidemiology lacks temporal and environmental complexity needed to smoke out endotypes

![](_page_4_Picture_4.jpeg)

# Scaling-up

#### Multi-cohort

- Different windows on calendar time
- Different windows on human development
- Variety of **populations**
- Variety of environments
- Multi-disciplinary and multi-perspective
  - Biostatistics (deductive) and machine-learning (inductive)
  - Tapestry of **reasoning** about mechanisms
- Hypothesis forming and following

![](_page_5_Picture_10.jpeg)

# **Health Data: No Mining Please**

![](_page_6_Figure_1.jpeg)

...Health is measured with **error** and **missingness**: Endo-phenotypes are resolved as if the researcher was looking through a prism and doyley at the problem

![](_page_6_Picture_3.jpeg)

# Hypothesising with Data

![](_page_7_Figure_1.jpeg)

## **New Asthma Risk Factor Found**

![](_page_8_Figure_1.jpeg)

## **Cross Cohort Team Research**

#### Data & Harmonized Metadata from Cohorts

MRC STELAR Consortium: www.asthmaelab.org

![](_page_9_Picture_3.jpeg)

# 'Learned' Atopy Classes Portable

![](_page_10_Figure_1.jpeg)

Lazic et al, Allergy 2013; 68(6): 764-70

![](_page_10_Picture_3.jpeg)

## **Risk Factor Development**

![](_page_11_Figure_1.jpeg)

Belgrave et al, Am J Respir Crit Care Med 2014;189(9):1101-9

![](_page_11_Picture_3.jpeg)

# **Assumed Biology: Atopic March**

- Progression of allergy
  Eczema → Asthma → Rhinitis
- Inferred from **population** summary  $\rightarrow$
- Assumed causal link between eczema – asthma & rhinitis
- Clinical response: target children with eczema to reduce progression to asthma

![](_page_12_Figure_5.jpeg)

From: World Allergy Organization, 2014

![](_page_12_Figure_7.jpeg)

![](_page_12_Picture_8.jpeg)

## Individual-level Longitudinal Analysis

![](_page_13_Figure_1.jpeg)

# Myth Bust by Learning from Data

![](_page_14_Figure_1.jpeg)

MRC | Medical Research Council

MRC STELAR consortium working at scale across MAAS and ALSPACS cohorts

![](_page_14_Picture_4.jpeg)

From: Belgrave et al. Developmental Profiles of Eczema, Wheeze, and Rhinitis: Two Population-Based Birth Cohort Studies. PlosMedicine 2014

# Joined-up Bio-Health Modelling

![](_page_15_Figure_1.jpeg)

## **Real World Phenomarking**

**Primary Care** 

**Renal Medicine** 

Diabetology

generate real world evidence on gliflozins His GP... Lifestyle factors: diet, exercise

?how to

His nephrologist...

**BP** control

Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann. Fam. 2009;7:357–363. ↑ Weight → ↑ BP

3 x evidence pipelines

1 x complex patient

Total evidence-base

predicts < 30% outcomes

#### Mr Jones...

![](_page_16_Picture_7.jpeg)

#### His diabetologist...

Glucose control

![](_page_16_Picture_10.jpeg)

# **Dual Therapy for Diabetes**

![](_page_17_Figure_1.jpeg)

## Data: Does Size Matter?

#### DATA

#### **METHODS & OUTPUTS**

# TSUNAMI HAZARD ZONE<br/>IN CASE OF EARTHOUAKE GO<br/>TO HIGH GROUND OR INLANDImage: Constant of the second sec

More data \* small-scale research = more small-scale research >n with >heterogeneity can *reduce* 'power'

Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005 Aug;2 (8):e124.

Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for evidence based epidemiology. Drug Saf. 2013 Oct;36 Suppl 1:S5-14.

![](_page_18_Picture_7.jpeg)

**EXPERTISE** 

## **Beyond In-licensed Data**

![](_page_19_Figure_1.jpeg)

# **Key Local Metadata**

![](_page_20_Figure_1.jpeg)

![](_page_21_Figure_0.jpeg)

## **Connected Health Cities**

![](_page_22_Figure_1.jpeg)

## **Clinical Outcome Prediction**

![](_page_23_Figure_1.jpeg)

Production line of clinical prediction models is broken

EU Directive 2007/47: The law now sees algorithms as medical devices

![](_page_23_Picture_4.jpeg)

From G. Hickey & B. Bridgewater

## **Health System Extension: Mobile**

Aim: To Reduce Relapse in Schizophrenia via Smartphone Drug + behaviour (information \* psychological endotype) = outcome

![](_page_24_Figure_2.jpeg)

# **Digital Health Triangle**

![](_page_25_Figure_1.jpeg)

#### Digital Health Economy (20\*\*?)

Ubiquitous technologies Unifying models Usable interfaces (avatar etc.) Stratification ↔ personalisation Actionable micro-evidence Service ↔ research

![](_page_25_Figure_4.jpeg)

# Depth, Trust and Scale

PUBLIC TRUST PUBLIC TRUST Learning Health System e.g. "Connected Health City"

<sup>o</sup>atient / Mobile Data

Shared Care Record

Molecular characterisation

Core Outcomes

**Dynamic Prediction Models** 

**Clinical Performance Networks** 

Routine Randomisation

Learning from Other Systems

From care + data → research → translation

![](_page_26_Picture_11.jpeg)

To a federation of research in care: pulled & shaped by local communities, with academic and industry partners

# Sub-disease Research Tips

- 1. Target
  - Plausible diagnostic **aggregation**
  - Unexplained **variation** in clinical outcomes
- 2. Data
  - Multiple populations/settings (heterogeneity & replication)
  - Useful **temporal** structure
- 3. Analytics
  - Multi-perspective ML **pre-model framing** don't rush in!
  - Heuristic **phenomarker-biomarker** resolution

![](_page_27_Picture_10.jpeg)